Ibrahim Ethem Ozsoy1, Mehmet Akif Tezcan1, Seda Guzeldag2, Ayse Turunc Ozdemir3. 1. Department of Thoracic Surgery, Kayseri Health Practice and Research Centre, University of Health Sciences, Turkey. 2. Department of Intensive Care Unit, Kayseri Health Practice and Research Centre, University of Health Sciences, Turkey. 3. Department of Infection Diseases, Kayseri Health Practice and Research Centre, University of Health Sciences, Turkey.
Abstract
OBJECTIVE: To determine the risk factors for spontaneous pneumomediastinum (SPM), its clinical course and effect on prognosis in patients with Coronavirus disease-19 (COVID-19) pneumonia. STUDY DESIGN: Descriptive study. PLACE AND DURATION OF STUDY: Kayseri City Training and Research Hospital, Turkey, from April to September 2020. METHODOLOGY: All COVID-19 patients' clinical, laboratory, and radiologic characteristics, as well as treatment outcome data, were obtained through medical record extraction. Group A had 50 patients (22 men and 28 women) without SPM, and Group B had 20 patients (10 men and 10 women) with SPM. RESULTS: Considering the accompanying comorbidities, the frequencies of asthma and inhaler-use was significantly higher in Group B than in Group A (p <0.05). In the CT evaluation at presentation, the rate of involvement of all five lobes of the lung in Group B was significantly higher than in Group A. Rates of tube thoracostomy, mechanical ventilator requirement, length of stay in hospital, and exitus were significantly higher in Group B than in Group A (p <0.05). CONCLUSION: SPM development in a patient with COVID-19 pneumonia is a sign that the prognosis will not be good, and these patients need a more aggressive treatment. Key Words: Spontaneous pneumomediastinum, COVİD-19, Pneumothorax, Real-time polymerase chain reaction, Subcutaneous emphysema.
OBJECTIVE: To determine the risk factors for spontaneous pneumomediastinum (SPM), its clinical course and effect on prognosis in patients with Coronavirus disease-19 (COVID-19) pneumonia. STUDY DESIGN: Descriptive study. PLACE AND DURATION OF STUDY: Kayseri City Training and Research Hospital, Turkey, from April to September 2020. METHODOLOGY: All COVID-19patients' clinical, laboratory, and radiologic characteristics, as well as treatment outcome data, were obtained through medical record extraction. Group A had 50 patients (22 men and 28 women) without SPM, and Group B had 20 patients (10 men and 10 women) with SPM. RESULTS: Considering the accompanying comorbidities, the frequencies of asthma and inhaler-use was significantly higher in Group B than in Group A (p <0.05). In the CT evaluation at presentation, the rate of involvement of all five lobes of the lung in Group B was significantly higher than in Group A. Rates of tube thoracostomy, mechanical ventilator requirement, length of stay in hospital, and exitus were significantly higher in Group B than in Group A (p <0.05). CONCLUSION: SPM development in a patient with COVID-19 pneumonia is a sign that the prognosis will not be good, and these patients need a more aggressive treatment. Key Words: Spontaneous pneumomediastinum, COVİD-19, Pneumothorax, Real-time polymerase chain reaction, Subcutaneous emphysema.
Authors: James Melhorn; Andrew Achaiah; Francesca M Conway; Elizabeth M F Thompson; Erik W Skyllberg; Joseph Durrant; Neda A Hasan; Yasser Madani; Prasheena Naran; Bavithra Vijayakumar; Matthew J Tate; Gareth E Trevelyan; Irfan Zaki; Catherine A Doig; Geraldine Lynch; Gill Warwick; Avinash Aujayeb; Karl A Jackson; Hina Iftikhar; Jonathan H Noble; Anthony Y K C Ng; Mark Nugent; Philip J Evans; Robert A Hastings; Harry R Bellenberg; Hannah Lawrence; Rachel L Saville; Nikolas T Johl; Adam N Grey; Huw C Ellis; Cheng Chen; Thomas L Jones; Nadeem Maddekar; Shahul Leyakathali Khan; Ambreen Iqbal Muhammad; Hakim Ghani; Yadee Maung Maung Myint; Cecillia Rafique; Benjamin J Pippard; Benjamin R H Irving; Fawad Ali; Viola H Asimba; Aqeem Azam; Eleanor C Barton; Malvika Bhatnagar; Matthew P Blackburn; Kate J Millington; Nicholas J Budhram; Katherine L Bunclark; Toshit P Sapkal; Giles Dixon; Andrew J E Harries; Mohammad Ijaz; Vijayalakshmi Karunanithi; Samir Naik; Malik Aamaz Khan; Karishma Savlani; Vimal Kumar; Beatriz Lara Gallego; Noor A Mahdi; Caitlin Morgan; Neena Patel; Elen W Rowlands; Matthew S Steward; Richard S Thorley; Rebecca L Wollerton; Sana Ullah; David M Smith; Wojciech Lason; Anthony J Rostron; Najib M Rahman; Rob J Hallifax Journal: Eur Respir J Date: 2022-05-12 Impact factor: 33.795